Skip to content
DataLookout
Menu

NCT06386315

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 17 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 30, 2027 to May 30, 2029 Show 5 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Study completion pushed from May 30, 2027 to May 30, 2031
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
    • Site details revised at 1 of 7 sites
  2. Notable Primary and study completion dates: May 30, 2026 to May 30, 2027
    • Site contacts updated at 2 of 7 sites
    v16
  3. Minor Study description expanded, about 1 wordv15
  4. Notable Eligibility criteria expanded, about 3 wordsv14
  5. Minor Study description expanded, about 5 wordsv13
Show 11 earlier versionsHide 11 earlier versions
  1. Notable Eligibility criteria shortened, about 1 wordv12
  2. Notable Eligibility criteria expanded, about 3 words
    • Site contacts updated at 7 of 7 sites
    v11
  3. Minor Study description expanded, about 17 words
    • Site details revised at 7 of 7 sites
    v10
  4. Notable Eligibility criteria expanded, about 3 words
    • Study sites: 3 to 7
    • Secondary endpoints: details revised at 1 of 3 entries
    v9
  5. Minor Site details revised at 3 of 3 sitesv8
  6. Minor Site details revised at 1 of 3 sitesv7
  7. Notable Enrollment target: 40 to 112
    • Site contacts updated at 3 of 3 sites
    v6
  8. Notable Primary and study completion dates: May 30, 2024 to May 30, 2026v5
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2024 to May 15, 2024
    • Site details revised at 3 of 3 sites
    v4
  10. Notable Enrollment target: 112 to 40v3
  11. Minor Secondary endpoints: details revised at 1 of 3 entriesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of grade 2 or higher acute adverse events (AEs)
Timeframe: Up to 14 days after radiation treatment

Secondary (3)

Response rate
Time to progression rate
Patient reported quality of life

Arms and interventions

ARM 1 (reduced dose ISRT)Experimental

Patients undergo reduced dose ISRT once daily (excluding weekends): 9 Gy delivered in 3 treatment fractions or 8 Gy in 2 fractions. At physician discretion, patients may receive 10 Gy in 5 fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

ARM 2 (SOC ISRT)Active comparator

Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends): 24 Gy in 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

Procedures: Computed Tomography, Endoscopic Procedure, Positron Emission Tomography

Radiation: Involved-site Radiation Therapy (3 Fractions), Involved-site Radiation Therapy (12 Fractions)

Other: Questionnaire Administration

Sites

7 sites in 1 country